Publications by authors named "Craig D Boyle"

Claim this Profile
A
Azabicyclic sulfonamides as potent 11beta-HSD1 inhibitors.
Unmesh Shah, Craig D Boyle, Samuel Chackalamannil, Hana Baker, Timothy Kowalski

Bioorg Med Chem Lett· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors.
Santhosh F Neelamkavil, Craig D Boyle, Samuel Chackalamannil, William J Greenlee, Lili Zhang

Bioorg Med Chem Lett· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents.
Craig D Boyle, Timothy J Kowalski

Expert Opin Ther Pat· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists.
Unmesh Shah, Claire M Lankin, Craig D Boyle, Samuel Chackalamannil, William J Greenlee

Bioorg Med Chem Lett· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A2A receptor antagonists.
Unmesh Shah, Craig D Boyle, Samuel Chackalamannil, Bernard R Neustadt, Neil Lindo

Bioorg Med Chem Lett· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in the discovery of 11beta-HSD1 inhibitors.
Craig D Boyle

Curr Opin Drug Discov Devel· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Craig D Boyle, Ruo Xu, Theodros Asberom, Samuel Chackalamannil, John W Clader

Bioorg Med Chem Lett· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction.
Dmitri A Pissarnitski, Theodros Asberom, Craig D Boyle, Samuel Chackalamannil, Madhu Chintala

Bioorg Med Chem Lett· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationship studies: M2 and CCR5 receptor antagonists.
Craig D Boyle, Anandan Palani

Curr Top Med Chem· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancement of pharmacokinetic properties and in vivo efficacy of benzylidene ketal M(2) muscarinic receptor antagonists via benzamide modification.
Craig D Boyle, Susan F Vice, Jennifer Campion, Samuel Chackalamannil, Claire M Lankin

Bioorg Med Chem Lett· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving the oral efficacy of CNS drug candidates: discovery of highly orally efficacious piperidinyl piperidine M2 muscarinic receptor antagonists.
Yuguang Wang, Samuel Chackalamannil, Zhiyong Hu, William J Greenlee, John Clader, Craig D Boyle

J Med Chem· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors.
Yuguang Wang, Samuel Chackalamannil, Zhiyong Hu, Craig D Boyle, Claire M Lankin

Bioorg Med Chem Lett· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of mono- and difluoronaphthoic acids.
Jayaram R Tagat, Stuart W McCombie, Dennis V Nazareno, Craig D Boyle, Joseph A Kozlowski

J Org Chem· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis